Edwards Lifesciences Files 8-K

TL;DR

Edwards Lifesciences filed an 8-K. Check for new disclosures.

AI Summary

On September 3, 2024, Edwards Lifesciences Corporation filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided text, suggesting it may be a routine filing or related to exhibit submissions.

Why It Matters

This filing indicates Edwards Lifesciences is providing updates or submitting required documentation to the SEC, which could contain important disclosures for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification without specific material events or financial impacts detailed.

Key Players & Entities

• Edwards Lifesciences Corp (company) — Filer
• September 3, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Irvine, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
• $1.5 billion — ed that its Board of Directors approved $1.5 billion of additional share repurchase authoriz
• $500 million — the Company announced its entry into a $500 million accelerated share repurchase agreement.

Filing Documents

• ew-20240903.htm (8-K) — 32KB
• ccpressrelease.htm (EX-99) — 11KB
• ew45percentblacklrga21-ewl.jpg (GRAPHIC) — 625KB
• 0001099800-24-000082.txt ( ) — 1024KB
• ew-20240903.xsd (EX-101.SCH) — 2KB
• ew-20240903_lab.xml (EX-101.LAB) — 21KB
• ew-20240903_pre.xml (EX-101.PRE) — 12KB
• ew-20240903_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 3, 2024, Edwards Lifesciences Corporation (the "Company") issued a press release announcing that the Company has completed its previously disclosed sale of the Company's Critical Care product group to Becton, Dickinson and Company. In the same press release, the Company announced that its Board of Directors approved $1.5 billion of additional share repurchase authorization. Also in the same press release, the Company announced its entry into a $500 million accelerated share repurchase agreement. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Edwards Lifesciences Corporation, dated September 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2024 EDWARDS LIFESCIENCES CORPORATION By: /s/ Linda J. Park Linda J. Park Senior Vice President, Associate General Counsel, and Corporate Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR